20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

AZD2820: Development discontinued

Palatin said partner AstraZeneca discontinued AZD2820. In June, AstraZeneca halted a Phase I trial after it could not exclude that a serious adverse event was linked to the compound (see BioCentury, June 25). Despite the...
00:33 , Sep 8, 2012 |  BC Extra  |  Company News

AZN discontinues AZD2820

Palatin Technologies Inc. (NYSE:PTN) said partner AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued AZD2820 , a melanocortin (MC) receptor partial agonist that was in development for obesity. In June, AstraZeneca halted a Phase I trial after it...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Clinical News

AZD2820: Phase I halted

Palatin said partner AstraZeneca halted a single-blind, placebo-controlled, Phase I trial evaluating AZD2820 in obese men following a serious adverse event in 1 patient. Palatin said the patient may have had an allergic reaction following...
00:47 , Jun 20, 2012 |  BC Extra  |  Clinical News

Palatin falls as obesity trial halted

Palatin Technologies Inc. (NYSE-A:PTN) fell $0.09 (17%) to $0.43 on Tuesday after partner AstraZeneca plc (LSE:AZN; NYSE:AZN) halted a Phase I trial of AZD2820 in obese men following a serious adverse event in one patient....
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Drais, Seldar, Astellas deal

Astellas and Drais partnered to form virtual company - Seldar Pharma Inc. - that will develop and commercialize Astellas' ASP7147 for irritable bowel syndrome with diarrhea. Seldar, which will be managed by Drais' executive team,...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Drais, Telsar Pharmaceuticals Inc., Astellas deal

Astellas and Drais partnered to form virtual company Telsar to develop and commercialize Astellas' ulcerative colitis (UC) compound ASP3291 . Telsar will be managed by Drais' executive team. Telsar will own all rights and assets...